This content is intended for healthcare professionals only.
Non-professionals may click “Cancel.”

Cancel

Confirmed

Product User Manual Illustrations

Working Towards a World Free of Tuberculosis

Harmony in Vision, Commitment at Heart

Dedicated to Excellence, Devoted to People

To Become a Key Driver in the Global Health Ecosystem,
Fostering Sustainable Development in Life Sciences

We offer full life-cycle pharmaceutical solutions from
pioneering innovation to wide benefit for end users

ZHONGNUO CARING HEALTH INDUSTRY (HAINAN) CO., LTD. is located in the Hainan Free Trade Port, positioning itself at the forefront of Chinese health industry with a global outlook. Guided by the mission of "Dedicated to Excellence, Devoted to people" and rooted in the core values of "Excellence, Innovation, Commitment, Sharing ", we are committed to becoming a pivotal driver of the global health ecosystem, leveraging technology to enhance health and upholding responsibility to safeguard life.

Our Position in DR-TB Prevention and Treatment
Pillar and Leader in MDR-TB Prevention and Treatment

With sustained R&D investment and strategic planning, we comprehensively cover the preferred and core drugs recommended by WHO and Chinese guidelines for DR-TB to build an end-to-end prevention and treatment system.

Benefit Society with
High-Quality Pharmaceuticals

Bedaquiline Fumarate Tablets (Brand name: Saiteshun)
Launched in China in December 2021, Bedaquiline is the first generic drug in the country passing the quality consistency evaluation

For contraindications and adverse reactions, please refer to the package insert.

Bedaquiline Fumarate Tablets (Brand name: Saiteshun)

Launched in China in December 2021, Saiteshun is the first generic drug in the country passing the quality consistency evaluation, breaking the monopoly of imported counterparts in its class. It is used as part of a combination therapy for multidrug-resistant pulmonary tuberculosis (MDR-TB) in adolescents aged 12 to <18 years weighing ≥30 kg, as well as in adults (≥18 years) with MDR-TB.

 

For contraindications and adverse reactions, please refer to the package insert.

胶囊型

Cycloserine Capsules (Brand name:Dasilikang)
Launched in China in 2014, It utilizes patented German packaging materials to ensure drug efficacy and shelf life of 30 months It’s a core therapeutic in the treatment of DR-TB.

For contraindications and adverse reactions, please refer to the package insert.

Cycloserine Capsules (Brand name:Dasilikang)

Launched in China in 2014, Dasilikang is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate.. It utilizes patented German packaging materials to ensure drug efficacy and shelf life of 30 months It’s a core therapeutic in the treatment of DR-TB.

For contraindications and adverse reactions, please refer to the package insert.

片型

Linezolid Tablets (Brand name: Linaitong)
Linezolid is an anti-infective medine imported from India. It received U.S. FDA approval in 2015 and was launched in China in November 2024.

For contraindications and adverse reactions, please refer to the package insert.

Linezolid Tablets (Brand name: Linaitong)

Linaitong is an anti-infective medine imported from India. It received U.S. FDA approval in 2015 and was launched in China in November 2024. As one of the core drugs in regimens for drug-resistant tuberculosis, it is now widely used in the treatment of MDR-TB.

For contraindications and adverse reactions, please refer to the package insert.

仪器

S6000 PLUS Liquid Chromatography
Approved in 2025, this product enables accurate monitoring of anti-tuberculosis drug concentrations through ultra-high performance liquid chromatography (UHPLC) technology, providing key support for individualized tuberculosis treatment.
S6000 PLUS Liquid Chromatography

Approved in 2025, this product enables accurate monitoring of anti-tuberculosis drug concentrations through ultra-high performance liquid chromatography (UHPLC) technology, providing key support for individualized tuberculosis treatment. 

针剂型

Ropeginterferon Alfa-2b Injection (Brand name: Besremi)
Ropeginterferon Alfa-2b Injection is an innovative ultra-long-acting interferon. Approved in China in June 2024.

For contraindications and adverse reactions, please refer to the package insert.

Ropeginterferon Alfa-2b Injection (Brand name: Besremi)

Besremi is an innovative ultra-long-acting interferon. Approved in China in June 2024, it is the first and only drug in China approved for the treatment of polycythemia vera (PV) in adults, filling the long-standing gap of no standardized therapeutic drugs in the domestic PV field. It is also the first innovative blood tumor drug deployed by our company. 

For contraindications and adverse reactions, please refer to the package insert.

We focus on the research and industrialization of
innovative drugs in the scientific and pharmaceutical fields.
Pioneering an Innovative Business Model

Our company adheres to its mission of "Dedicated to Excellence, Devoted to people ", focusing on critical disease areas such as tuberculosis and collaborating with international pharmaceutical companies to accelerate technology localization. We deeply implement the Marketing Authorization Holder (MAH) system and builds a full life cycle quality system in line with international standards. Leveraging over a decade of expertise in the tuberculosis field, we continue investing in R&D, establishing proprietary intellectual property technology platforms and product pipelines to drive sustainable growth.

Forging Excellence with Global Standards

Abiding by high international standards such as that of the U.S. FDA, we implement a tiered supplier management system and full-chain monitoring for medicines and medical devices, and equip with intelligent temperature-controlled cold chain systems with ±0.5°C precision for high-value specialty drugs. Relying on its self-built, high-standard quality management system and supply chain capabilities, we oversee and validate every step of production, storage, and transportation to ensure the products are complied with the Chinese Pharmacopoeia and national regulations. Additionally, we have established an end-to-end digital traceability system covering the entire product life cycle to guarantee patient medication safety.

Intelligent Supply Chain: Precise and Efficient Delivery

Our company is equipped with a comprehensive professional pharmaceutical grade cold chain logistics system to safeguard drug safety. Leveraging multi-center smart warehouses in Hainan, Henan, and other locations, we have established a nationwide collaborative network. By employing intelligent algorithms to optimize logistics matching, we accelerate supply chain operations and enhance drug accessibility. Furthermore, we have developed smart order and logistics systems that provide visible inventory management and real-time order tracking, thereby improving overall operational efficiency and customer experience.

Deep Industry Academia Research Integration, Cultivating the Future

Industry-University-Research Integration for Future Co-Creation

University-Enterprise Partnership, Exploring New Frontiers:Our company established in-depth strategic cooperation with top domestic pharmaceutical universities. The cooperation covers multiple dimensions, including co-building internship and talent incubation bases, hosting high-level academic forums, launching joint customized talent development programs, and conducting cutting-edge scientific research. With major scientific research projects as the link, we drive the cultivation of innovative talents and accelerate the efficient transformation and in-depth integration of cutting-edge research achievements from universities with the industrialization needs of companies.

01
Pioneering an Innovative Business Model
02
Forging Excellence with Global Standards
03
Intelligent Supply Chain: Precise and Efficient Delivery
04
Deep Industry Academia Research Integration, Cultivating the Future
News Center